• LAST PRICE
    0.6400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.6000/ 21
  • Ask / Lots
    0.6720/ 3
  • Open / Previous Close
    0.0000 / 0.6400
  • Day Range
    ---
  • 52 Week Range
    Low 0.5040
    High 1.8294
  • Volume
    35
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.6302
TimeVolumeAKTX
09:52 ET1000.6389
10:10 ET4000.614449
10:21 ET104000.6144
11:24 ET9900.62
01:08 ET54500.634
01:10 ET6000.634
01:17 ET2500.6399
01:26 ET82010.6342
01:28 ET64000.6341
02:08 ET5000.6341
02:09 ET111000.634
03:30 ET57500.6401
03:32 ET324240.65191
03:38 ET1000.65
03:43 ET3000.65
03:45 ET5000.65
03:48 ET120860.6162
03:56 ET136350.64
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAKTX
Akari Therapeutics PLC
40.9M
-1.8x
---
United StatesRUBY
Rubius Therapeutics Inc
43.3M
-0.2x
---
United StatesAMTI
Applied Molecular Transport Inc.
39.3M
-0.3x
---
United StatesASLN
Aslan Pharmaceuticals Ltd
42.2M
-1.2x
---
United StatesBTTX
Better Therapeutics Inc
41.3M
-0.7x
---
United StatesNRXP
NRX Pharmaceuticals Inc
49.2M
-0.5x
---
As of 2022-10-05

Company Information

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5. Its lead product candidate, Nomacopan, is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (membrane attack complex (MAC)), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. The Company’s pipeline includes two late-stage programs for bullous pemphigoid (BP) and thrombotic microangiopathy (TMA), as well as earlier stage research and development programs in eye and lung diseases with unmet need. Its pre-clinical programs include Nomacopan LA, Votucalis and others.

Contact Information

Headquarters
24 W 40th St Fl 8NEW YORK, NY, United States 10018-1028
Phone
646-350-0702
Fax
646-843-9352

Executives

Executive Chairman of the Board
Raymond Prudo-chlebosz
President, Chief Executive Officer, Director
Rachelle Jacques
Chief Financial Officer
Torsten Hombeck
Chief Operating Officer
Melissa Bradford-klug
Director
Michael Grissinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$40.9M
Revenue (TTM)
$0.00
Shares Outstanding
744.5K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.42
EPS
$-0.36
Book Value
$0.12
P/E Ratio
-1.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.